Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2014; 20(43): 15965-15974
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15965
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.15965
New treatments for chronic hepatitis C: An overview for paediatricians
Daniele Serranti, Department of Health Sciences, University of Florence, I-50139 Firenze, Italy
Giuseppe Indolfi, Massimo Resti, Paediatric and Liver Unit, Meyer Children’s University Hospital of Florence, I-50139 Firenze, Italy
Author contributions: Indolfi G and Serranti D contributed equally to this work; Indolfi G and Serranti D performed the literature research and wrote the first draft of the manuscript; Resti M revised the entire document.
Correspondence to: Giuseppe Indolfi, MD, Paediatric and Liver Unit, Meyer Children’s University Hospital of Florence, Viale G. Pieraccini 24, I-50139 Firenze, Italy. g.indolfi@meyer.it
Telephone: +39-55-5662410 Fax: +39-55-5664000
Received: December 3, 2013
Revised: June 23, 2014
Accepted: August 13, 2014
Published online: November 21, 2014
Revised: June 23, 2014
Accepted: August 13, 2014
Published online: November 21, 2014
Core Tip
Core tip: The discovery of new drugs and new therapeutic regimens is changing radically the approach to chronic hepatitis C virus infection. The efficacy and safety of pegylated interferons (IFNs) and ribavirin are well known in children. The introduction of direct antiviral agents has already changed the standard of care in adults. Other new drugs and IFN free regimens have been proposed with promising results. This scenario could pone new perspectives in treatment of children with chronic hepatitis C.